Literature DB >> 10775638

Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses.

S Y Chan1, R F Speck, M C Ma, M A Goldsmith.   

Abstract

Since the Marburg (MBG) and Ebola (EBO) viruses have sequence homology and cause similar diseases, we hypothesized that they associate with target cells by similar mechanisms. Pseudotype viruses prepared with a luciferase-containing human immunodeficiency virus type 1 backbone and packaged by the MBG virus or the Zaire subtype EBO virus glycoproteins (GP) mediated infection of a comparable wide range of mammalian cell types, and both were inhibited by ammonium chloride. In contrast, they exhibited differential sensitivities to treatment of target cells with tunicamycin, endoglycosidase H, or protease (pronase). Therefore, while they exhibit certain functional similarities, the MBG and EBO virus GP interact with target cells by distinct processes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10775638      PMCID: PMC112022          DOI: 10.1128/jvi.74.10.4933-4937.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  18 in total

1.  [The penetration of the Marburg virus into eukaryotic cells].

Authors:  R F Mar'iankova; S E Glushakova; E V Pyzhik; I S Lukashevich
Journal:  Vopr Virusol       Date:  1993 Mar-Apr

2.  A system for functional analysis of Ebola virus glycoprotein.

Authors:  A Takada; C Robison; H Goto; A Sanchez; K G Murti; M A Whitt; Y Kawaoka
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

3.  Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation.

Authors:  J E Hildreth; R J Orentas
Journal:  Science       Date:  1989-06-02       Impact factor: 47.728

4.  The cytoplasmic domain of the interleukin-2 receptor beta chain contains both unique and functionally redundant signal transduction elements.

Authors:  M A Goldsmith; W Xu; M C Amaral; E S Kuczek; W C Greene
Journal:  J Biol Chem       Date:  1994-05-20       Impact factor: 5.157

5.  Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range.

Authors:  N R Landau; K A Page; D R Littman
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

6.  Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus.

Authors:  A Sanchez; M P Kiley; B P Holloway; D D Auperin
Journal:  Virus Res       Date:  1993-09       Impact factor: 3.303

7.  The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing.

Authors:  A Sanchez; S G Trappier; B W Mahy; C J Peters; S T Nichol
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

8.  Marburg virus gene 4 encodes the virion membrane protein, a type I transmembrane glycoprotein.

Authors:  C Will; E Mühlberger; D Linder; W Slenczka; H D Klenk; H Feldmann
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

9.  Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes.

Authors:  R I Connor; B K Chen; S Choe; N R Landau
Journal:  Virology       Date:  1995-02-01       Impact factor: 3.616

10.  Variation in the glycoprotein and VP35 genes of Marburg virus strains.

Authors:  A Sanchez; S G Trappier; U Ströher; S T Nichol; M D Bowen; H Feldmann
Journal:  Virology       Date:  1998-01-05       Impact factor: 3.616

View more
  59 in total

1.  Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity.

Authors:  N Chazal; G Singer; C Aiken; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

Review 2.  Vaccine and adjuvant design for emerging viruses: mutations, deletions, segments and signaling.

Authors:  Gavin C Bowick; Alexander J McAuley
Journal:  Bioeng Bugs       Date:  2011-05-01

3.  Folate receptor alpha and caveolae are not required for Ebola virus glycoprotein-mediated viral infection.

Authors:  Graham Simmons; Andrew J Rennekamp; Ning Chai; Luk H Vandenberghe; James L Riley; Paul Bates
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

4.  Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding.

Authors:  Ziying Han; Hani Boshra; J Oriol Sunyer; Susan H Zwiers; Jason Paragas; Ronald N Harty
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

Review 5.  Altering the tropism of lentiviral vectors through pseudotyping.

Authors:  James Cronin; Xian-Yang Zhang; Jakob Reiser
Journal:  Curr Gene Ther       Date:  2005-08       Impact factor: 4.391

6.  Studies of ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha.

Authors:  Akihito Yonezawa; Marielle Cavrois; Warner C Greene
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 7.  Emerging targets and novel approaches to Ebola virus prophylaxis and treatment.

Authors:  Jin Huk Choi; Maria A Croyle
Journal:  BioDrugs       Date:  2013-12       Impact factor: 5.807

8.  Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity.

Authors:  Rachel L Kaletsky; Graham Simmons; Paul Bates
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

9.  Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition.

Authors:  Osvaldo Martinez; Joshua Johnson; Balaji Manicassamy; Lijun Rong; Gene G Olinger; Lisa E Hensley; Christopher F Basler
Journal:  Cell Microbiol       Date:  2009-09-22       Impact factor: 3.715

10.  Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors.

Authors:  Ilias Christodoulopoulos; Magali E Droniou-Bonzom; Jill E Oldenburg; Paula M Cannon
Journal:  Retrovirology       Date:  2010-01-26       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.